USPTO serial 90765924
CYCART
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- HUSSAIN, TASNEEM
- Law office
- TMO LAW OFFICE 118- EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with CYCART?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
CAMILLE M. MILLER
Camille M. Miller COZEN O'CONNOR1650 MARKET STREETSUITE 2800PHILADELPHIA, PA 19103Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Bioengineered cells for use in scientific, laboratory and medical research; human allograft tissue made from human umbilical cords and human placentas for use in scientific, laboratory and medical research; placental-derived cells, chimeric antigen receptor (CAR) T cells, and placental-derived T cells with a chimeric antigen receptor (CAR), all for use in scientific, laboratory and medical research | ACTIVE | Jun 2, 2021 |
| 005 | Cells and biological preparations intended for medical and clinical use, namely, blood, stem cells, placental-derived cells, umbilical cord cells, placental-derived T cells, chimeric antigen receptor (CAR) T cells, umbilical cord blood, and placental allograft tissue; bioengineered cells for use in immunotherapies for cancer and other diseases; human allograft tissue made from human umbilical cords and human placentas intended for subsequent implantation; human amniotic membrane and human chorionic membrane intended for subsequent implantation; human collagen compositions and extracellular matrix compositions intended for subsequent implantation; biological products for medical use, namely, placental-derived natural killer cells, and placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen; biological tissue intended for use as a wound covering and burn dressing; wound dressings; burn dressings; surgical dressings; pharmaceutical preparations for wounds and burns; and written instructional materials distributed in connection with the aforesaid goods; biological products for medical use, namely, placental-derived cytotoxic T cells with a chimeric antigen receptor (CAR) specific for a cancer or other disease-associated antigen | ACTIVE | Jun 2, 2021 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 18, 2023 | EXPT | EXPARTE APPEAL TERMINATED | — |
| Aug 18, 2023 | EXDM | EXPARTE APPEAL DISMISSED AS MOOT | — |
| Jun 15, 2023 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 15, 2023 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 15, 2023 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 31, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 14, 2023 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 14, 2023 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 14, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 16, 2022 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Dec 16, 2022 | EXPI | EX PARTE APPEAL-INSTITUTED | — |
| Dec 16, 2022 | JURT | JURISDICTION RESTORED TO EXAMINING ATTORNEY | — |
| Dec 16, 2022 | EXAF | EXPARTE APPEAL RECEIVED AT TTAB | — |
| Jun 16, 2022 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jun 16, 2022 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jun 16, 2022 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 13, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 12, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 12, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 9, 2022 | AAUA | NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED | — |
| Mar 8, 2022 | IUAA | USE AMENDMENT ACCEPTED | — |
| Mar 8, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 8, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 8, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 1, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 2, 2021 | AUPC | AMENDMENT TO USE PROCESSING COMPLETE | — |
| Sep 2, 2021 | IUAF | USE AMENDMENT FILED | — |
| Aug 30, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 15, 2021 | EAAU | TEAS AMENDMENT OF USE RECEIVED | — |
| Jun 14, 2021 | NWAP | NEW APPLICATION ENTERED | — |